Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study

Table 3 Association between clinical response/remission and improvement in Patient Health Questionnaire–9 items total score at week 52/final visit–intent-to-treat and completers populations

Analysis population	Parameter	Model coefficient (SE)	Est. odds ratio (95%CI)	P value
Clinical response
ITT	Baseline PHQ-9 total score	0.17 (0.06)	1.19 (1.05-1.34)	0.005
	Clinical response at week 52: Yes versus No	0.30 (0.65)	1.35 (0.38-4.84)	0.648
	UC duration (years)	0.11 (0.05)	1.11 (1.00-1.24)	0.051
Completers	Baseline PHQ-9 total score	0.20 (0.10)	1.22 (1.00-1.48)	0.049
	Clinical response at week 52: Yes versus No	-1.29 (1.29)	0.28 (0.02-3.43)	0.317
	UC duration (years)	0.14 (0.08)	1.15 (0.98-1.35)	0.079
Clinical remission
ITT	Baseline PHQ-9 total score	0.28 (0.09)	1.33 (1.11-1.59)	0.002
	Clinical remission at week 52: Yes versus No	2.07 (0.88)	7.94 (1.42-44.41)	0.018
	UC duration (years)	0.11 (0.06)	1.11 (1.00-1.24)	0.054
Completers	Baseline PHQ-9 total score	0.22 (0.11)	1.24 (1.00-1.53)	0.045
	Clinical remission at week 52: Yes versus No	1.39 (1.07)	4.00 (0.50-32.37)	0.193
	UC duration (years)	0.14 (0.08)	1.15 (0.98-1.36)	0.095

Clinical response based on simple clinical colitis activity index (SCCAI): decrease from baseline of ≥ 2; Clinical remission: SCCAI ≤ 2; CI: Confidence interval; ITT: Intent-to-treat; PHQ-9: Patient Health Questionnaire–9 Items; SE: Standard error.